Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVCR – NovoCure Limited

NovoCure Limited
NVCR
$14.53
Name : NovoCure Limited
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $1,623,884,672.00
EPSttm : -1.56
finviz dynamic chart for NVCR
NovoCure Limited
$14.53
0.17%
$0.025

Float Short %

5.92

Margin Of Safety %

Put/Call OI Ratio

0.14

EPS Next Q Diff

-0.13

EPS Last/This Y

-0.02

EPS This/Next Y

-0.13

Price

14.51

Target Price

27.19

Analyst Recom

1.75

Performance Q

-17.19

Relative Volume

1

Beta

0.79

Ticker: NVCR




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08NVCR12.60.120.0329181
2025-09-09NVCR12.650.120.0629574
2025-09-10NVCR12.220.120.1129943
2025-09-11NVCR12.730.120.0529873
2025-09-12NVCR12.160.120.1730203
2025-09-15NVCR12.710.120.1330319
2025-09-16NVCR12.680.120.0731202
2025-09-17NVCR12.690.119527740048060.1680092059838932145
2025-09-18NVCR12.990.120.0532596
2025-09-22NVCR13.090.120.5829678
2025-09-23NVCR130.140.0530473
2025-09-24NVCR12.850.140.0230927
2025-09-25NVCR12.790.130.0731672
2025-09-26NVCR12.890.130.0432014
2025-09-29NVCR12.90.130.1832068
2025-09-30NVCR12.920.130.5332138
2025-10-01NVCR13.980.140.1132151
2025-10-02NVCR14.060.130.1632205
2025-10-03NVCR14.680.130.1832440
2025-10-06NVCR14.50.140.2933105
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08NVCR12.60-51.0-85.8-1.58
2025-09-09NVCR12.66-51.0-80.9-1.58
2025-09-10NVCR12.21-51.0-71.2-1.58
2025-09-11NVCR12.73-51.0-89.9-1.58
2025-09-12NVCR12.15-51.0-68.9-1.58
2025-09-15NVCR12.73-51.0-91.1-1.58
2025-09-16NVCR12.68-51.0-79.0-1.58
2025-09-17NVCR12.69-51.0-79.9-1.58
2025-09-18NVCR12.99-51.0-85.3-1.58
2025-09-19NVCR12.69-51.0-74.1-1.58
2025-09-22NVCR13.09-51.0-86.9-1.58
2025-09-23NVCR13.01-51.0-78.2-1.58
2025-09-24NVCR12.85-51.0-76.8-1.58
2025-09-25NVCR12.78-51.0-78.5-1.58
2025-09-26NVCR12.89-51.0-81.6-1.58
2025-09-29NVCR12.90-51.0-79.9-1.58
2025-09-30NVCR12.93-51.0-79.8-1.58
2025-10-01NVCR13.97-51.0-98.6-1.58
2025-10-02NVCR14.05-51.0-80.8-1.58
2025-10-03NVCR14.68-51.0-90.0-1.58
2025-10-06NVCR14.51-51.0-87.3-1.58
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08NVCR0.49-0.965.57
2025-09-09NVCR0.49-0.965.57
2025-09-10NVCR0.49-0.965.57
2025-09-11NVCR0.49-0.966.03
2025-09-12NVCR0.49-0.966.03
2025-09-15NVCR0.49-0.916.01
2025-09-16NVCR0.50-0.916.01
2025-09-17NVCR0.50-0.916.01
2025-09-18NVCR0.50-0.916.01
2025-09-19NVCR0.50-0.916.01
2025-09-22NVCR0.50-0.916.01
2025-09-23NVCR0.50-0.916.01
2025-09-24NVCR0.50-0.916.01
2025-09-25NVCR0.50-0.915.93
2025-09-26NVCR0.50-0.915.93
2025-09-29NVCR0.50-0.905.92
2025-09-30NVCR0.51-0.905.92
2025-10-01NVCR0.51-0.905.92
2025-10-02NVCR0.51-0.905.92
2025-10-03NVCR0.51-0.905.92
2025-10-06NVCR0.51-2.135.92
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.36

Avg. EPS Est. Current Quarter

-0.42

Avg. EPS Est. Next Quarter

-0.49

Insider Transactions

0.51

Institutional Transactions

-2.13

Beta

0.79

Average Sales Estimate Current Quarter

158

Average Sales Estimate Next Quarter

160

Fair Value

Quality Score

29

Growth Score

39

Sentiment Score

60

Actual DrawDown %

93.8

Max Drawdown 5-Year %

-95.2

Target Price

27.19

P/E

Forward P/E

PEG

P/S

2.57

P/B

4.64

P/Free Cash Flow

EPS

-1.56

Average EPS Est. Cur. Y​

-1.58

EPS Next Y. (Est.)

-1.71

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-27.13

Relative Volume

1

Return on Equity vs Sector %

-74

Return on Equity vs Industry %

-67.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-87.3
NovoCure Limited
Sector: Healthcare
Industry: Medical Devices
Employees: 1488
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
stock quote shares NVCR – NovoCure Limited Stock Price stock today
news today NVCR – NovoCure Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch NVCR – NovoCure Limited yahoo finance google finance
stock history NVCR – NovoCure Limited invest stock market
stock prices NVCR premarket after hours
ticker NVCR fair value insiders trading